These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 29206891)
1. Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. Karmali R; Kimby E; Ghielmini M; Flinn IW; Gordon LI; Zucca E Ann Oncol; 2018 Feb; 29(2):332-340. PubMed ID: 29206891 [TBL] [Abstract][Full Text] [Related]
3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061 [TBL] [Abstract][Full Text] [Related]
4. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma? Moccia AA; Zucca E; Ghielmini M Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427 [TBL] [Abstract][Full Text] [Related]
5. The role of obinutuzumab in the management of follicular lymphoma. O'Nions J; Townsend W Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699 [TBL] [Abstract][Full Text] [Related]
8. [The current therapeutic landscape for follicular lymphoma]. Kobayashi T Rinsho Ketsueki; 2021; 62(8):1070-1076. PubMed ID: 34497193 [TBL] [Abstract][Full Text] [Related]
9. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420 [TBL] [Abstract][Full Text] [Related]
10. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study. Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267 [TBL] [Abstract][Full Text] [Related]
11. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576 [TBL] [Abstract][Full Text] [Related]
12. Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden. Fukuhara N; Ishizawa K Jpn J Clin Oncol; 2019 Apr; 49(4):306-310. PubMed ID: 30715424 [TBL] [Abstract][Full Text] [Related]
13. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Feugier P Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779 [TBL] [Abstract][Full Text] [Related]
14. Treatment of follicular lymphoma: current status. Tilly H; Zelenetz A Leuk Lymphoma; 2008; 49 Suppl 1():7-17. PubMed ID: 18821428 [TBL] [Abstract][Full Text] [Related]